Gene Therapy for Wet AMD: New Phase 2 Data

Dante Pieramici MD

Show Description +

Dr. Pieramici shares data from the phase 2 OPTIC and LUNA trials of ixoberogene soroparvovec (ixo-vec, Adverum), an intravitreal gene therapy under investigation for wet AMD.

Posted: 5/12/2025

Keywords:

retina-meeting-recap

•

Wet AMD

•

Age-Related Macular Degeneration (AMD)

•

Gene Therapy

•

Clinical Trials

•

ixoberogene soroparvovec

•

ixo-vec

•

Adverum

Up Next

Name: Gene Therapy for Wet AMD: New Phase 2 Data
Uploaded: 2025-05-12T20:15:25+00:00
Description: Dr. Pieramici shares data from the phase 2 OPTIC and LUNA trials of ixoberogene soroparvovec (ixo-vec, Adverum), an intravitreal gene therapy under investigation for wet AMD.

Surgical Pearls for Sickle Cell Retinopathy

Jennifer I. Lim, MD

Dosing Considerations with 8 mg Aflibercept

Mark R. Barakat, MD

Pegcetacoplan in the Real World: Year 1

Mengxi Shen, MD, PhD

Phase 2a Data Revealed for AVD-104 (Aviceda)

Baruch D. Kuppermann, MD, PhD

Real-World Data for 8 mg Aflibercept

Vasileios Konidaris, MD, PhD

$The Benefits of Refractive Vitrectomy for SVOs$

The Benefits of Refractive Vitrectomy for SVOs

Paulo Eduardo Stanga, MD

Bariatric Surgery Versus GLP-1 Receptor Agonists

Christabel Chan, MD

Treating DR with Axitinib

Neal S. Shah, MD

Phase 2 Data on Gene Therapy for AMD

Christine Kay, MD

OCS-01 (Oculis) in DME: A Phase 3 Update

Carl Danzig, MD

Back to All Videos

Gene Therapy for Wet AMD: New Phase 2 Data

Dante Pieramici MD

Dr. Pieramici shares data from the phase 2 OPTIC and LUNA trials of ixoberogene soroparvovec (ixo-vec, Adverum), an intravitreal gene therapy under investigation for wet AMD.

Posted: 5/12/2025

Keywords:

retina-meeting-recap

•

Wet AMD

•

Age-Related Macular Degeneration (AMD)

•

Gene Therapy

•

Clinical Trials

•

ixoberogene soroparvovec

•

ixo-vec

•

Adverum

Please log in to leave a comment.

Meeting Coverage:

Association for Research in Vision & Ophthalmology

Gene Therapy for Wet AMD: New Phase 2 Data

Up Next

Gene Therapy for Wet AMD: New Phase 2 Data

More From ARVO: 2025 Coverage